Scheen Aj
Impact in
-
- Diabetes Treatment and Management
- Hormonal Regulation and Hypertension
-
- Blood Pressure and Hypertension Studies
- Renin-Angiotensin System Studies
Papers in
-
- Diabetes Treatment and Management 19
- Diabetes Management and Research 10
- Diabetes, Cardiovascular Risks, and Lipoproteins 2
- Physiology 11
- Diet and metabolism studies 10
- Co-authors
- Nicolas Paquot (5 shared papers)Marcelle Rorive (3 shared papers)Nicolas Paquot (3 shared papers)Stephan Rössner (1 shared paper)Luc F. Van Gaal (1 shared paper)Olivier Ziegler (1 shared paper)Bernard Jandrain (3 shared papers)Nathalie Esser (1 shared paper)
In The Last Decade
Scheen Aj
53 papers receiving 555 citations
Peers
Comparison fields: 5 of 81
- Endocrinology, Diabetes and Metabolism 296
- Cardiology and Cardiovascular Medicine 227
- Pharmacology 162
- Endocrine and Autonomic Systems 46
- Physiology 133
Countries citing papers authored by Scheen Aj
This map shows the geographic impact of Scheen Aj's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scheen Aj with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scheen Aj more than expected).
Fields of papers citing papers by Scheen Aj
This network shows the impact of papers produced by Scheen Aj. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scheen Aj. The network helps show where Scheen Aj may publish in the future.
Co-authors
The 22 scholars most cited alongside Scheen Aj, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 57 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 201 | |
| 2 | 2004 | 158 | |
| 3 | 1999 | 48 | |
| 4 | [Chronopharmacology and chronotherapeutics]. | 1985 | 41 |
| 5 | [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk]. | 2015 | 12 |
| 6 | Retinopathy, but not neuropathy, is influenced by the level of residual endogenous insulin secretion in type 2 diabetes. | 1995 | 10 |
| 7 | [Obesity, insulin resistance and type 2 diabetes: risk factors for breast cancer]. | 2011 | 7 |
| 8 | [Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study]. | 2002 | 7 |
| 9 | 2005 | 6 | |
| 10 | 2000 | 5 | |
| 11 | [Perspectives on atypical routes of insulin administration. Oral, rectal, and nasal routes]. | 1988 | 5 |
| 12 | [Type 2 diabetes: journey in the heart of a complex disease]. | 2012 | 5 |
| 13 | [Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR)]. | 2014 | 4 |
| 14 | [Type 2 diabetes and anti-inflammatory agents: new therapeutic prospects?]. | 2011 | 4 |
| 15 | [Clinical study of the month: ASTEROID: regression of coronary atherosclerosis with rosuvastatin at a maximal daily dose of 40 mg]. | 2006 | 4 |
| 16 | [Hypertension and diabetes: about a common but complex association]. | 2012 | 3 |
| 17 | [Benefits and limitations of protein diets in obese patients with type 2 diabetes]. | 1999 | 3 |
| 18 | [LIRAGUTIDE AT A DOSE OF 3.0 MG (SAXENDA): NEW INDICATION FOR THE TREATMENT OF OBESITY]. | 2016 | 3 |
| 19 | [Dulaglutide (Trulicity®), a new once-weekly agonist of glucagon-like peptide-1 receptors for type 2 diabetes]. | 2016 | 3 |
| 20 | High prevalence of diabetes mellitus and metabolic syndrome in the BEST study ("Belgian Evaluation of Screening and Treatment of high risk patients based on waist and age") | 2005 | 2 |
About Scheen Aj
Scheen Aj is a scholar working on Endocrinology, Diabetes and Metabolism, Physiology, Pharmacology, Surgery and Genetics, having authored 57 papers that have together received 578 indexed citations. Recurring topics across this work include Diabetes Treatment and Management (19 papers), Diabetes Management and Research (10 papers), Diet and metabolism studies (10 papers), Pharmacology and Obesity Treatment (9 papers), Metabolism, Diabetes, and Cancer (4 papers), Lipoproteins and Cardiovascular Health (4 papers), Diabetes and associated disorders (3 papers) and Diabetes, Cardiovascular Risks, and Lipoproteins (2 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (296 citations), Cardiology and Cardiovascular Medicine (227 citations), Pharmacology (162 citations), Endocrine and Autonomic Systems (46 citations) and Physiology (133 citations). Scheen Aj has collaborated with scholars based in Belgium, France and Sweden. Frequent co-authors include Nicolas Paquot, Marcelle Rorive, Nicolas Paquot, Stephan Rössner, Luc F. Van Gaal, Olivier Ziegler, Bernard Jandrain, Nathalie Esser, Philippe Schneiter and Luc Tappy. Their work appears in journals such as Diabetes & Metabolism, International Journal of Obesity, International Journal of Gynecology & Obstetrics, Diabetologia and The Lancet.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.